Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

All Monthly Communication Reports for Novartis Pharmaceuticals Canada Inc.

Mark Vineis, Country President (Corporation)

Learn more...

Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.

Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.

Results below are sorted by posted date, beginning with the most recent.

Results null-null of 93

  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    • Phillip Jennings, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2025-02-18
    Posted date: 2025-03-15
    Communication number: 15599-632584 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andrew Evans, Manager of Stakeholder Relations | Official Opposition | House of Commons
    • Bryce McRae, Manager of Stakeholder Relations | Conservative - House Officers | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-12-12
    Posted date: 2025-01-15
    Communication number: 15599-628171 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Michelle Boudreau, Associate Assistant Deputy Minister | Health Canada (HC)
    • Greg Orenscsak, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-10-15
    Posted date: 2024-11-15
    Communication number: 15599-620344 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Niloo Boroun, Director of Policy | Office of Minister International Trade | Global Affairs Canada (GAC)
    • Mary Ng, Minister of International Trade | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-10-15
    Posted date: 2024-11-15
    Communication number: 15599-620342 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Aaron Wudrick, Director of Policy | Office of the Official Opposition | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-09-26
    Posted date: 2024-10-15
    Communication number: 15599-616360 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-09-26
    Posted date: 2024-10-15
    Communication number: 15599-616359 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Valerie Bradford, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-09-24
    Posted date: 2024-10-15
    Communication number: 15599-616358 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Peter Fragiskatos, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-09-23
    Posted date: 2024-10-15
    Communication number: 15599-616357 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Matt Jeneroux, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-09-23
    Posted date: 2024-10-15
    Communication number: 15599-616356 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Pam Damoff, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-14
    Posted date: 2024-06-15
    Communication number: 15599-605004 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Benoit Leduc, Manager | Innovation, Science and Economic Development Canada (ISED)
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-14
    Posted date: 2024-06-15
    Communication number: 15599-605003 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-14
    Posted date: 2024-06-15
    Communication number: 15599-605000 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Julie Fielder, Special Assistant to MP Kmiec | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-13
    Posted date: 2024-06-15
    Communication number: 15599-605002 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Benjamin Wiles, Special Assistant to MP Damoff | House of Commons
    • Pam Damoff, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-07
    Posted date: 2024-06-15
    Communication number: 15599-604998 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)
    • Benoit Leduc, Manager | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-07
    Posted date: 2024-06-15
    Communication number: 15599-604997 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons
    • Julie Fielder, Special Assistant to MP Kmiec | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2024-05-07
    Posted date: 2024-06-15
    Communication number: 15599-604995 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Francesco Sorbara, Member of Parliment | House of Commons

    Subject Matter of the communication: Health, Industry, Research and Development
    Communication date: 2024-02-29
    Posted date: 2024-03-15
    Communication number: 15599-595436 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Rachel Blaney, Member of Parliament North Island Powell River | House of Commons

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2024-02-29
    Posted date: 2024-03-15
    Communication number: 15599-595435 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2024-02-29
    Posted date: 2024-03-15
    Communication number: 15599-595434 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2023-12-07
    Posted date: 2024-01-11
    Communication number: 15599-590071 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee, Assistant Deputy Minister | Director General's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2023-11-08
    Posted date: 2023-12-15
    Communication number: 15599-585830 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jessica La Forge, Policy Advisor | Pacific Economic Development Canada (PacifiCan)
    • Gurjiven Sandhu, Director of Policy | Pacific Economic Development Canada (PacifiCan)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2023-11-07
    Posted date: 2023-12-15
    Communication number: 15599-585825 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2023-11-06
    Posted date: 2023-12-15
    Communication number: 15599-585824 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Chandra Arya, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2023-11-06
    Posted date: 2023-12-15
    Communication number: 15599-585823 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Francesco Sorbara, Member of Parliment | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2023-11-06
    Posted date: 2023-12-15
    Communication number: 15599-585821 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Christopher Johnstone, Assistant Deputy minister | Health Canada (HC)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2023-09-20
    Posted date: 2023-10-16
    Communication number: 15599-577623 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mark Holland, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2023-08-17
    Posted date: 2023-09-15
    Communication number: 15599-575231 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2023-06-23
    Posted date: 2023-06-28
    Communication number: 15599-570777 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2023-06-22
    Posted date: 2023-07-15
    Communication number: 15599-570776 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2023-06-06
    Posted date: 2023-07-15
    Communication number: 15599-567885 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bianca Hossain, Policy advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2023-04-25
    Posted date: 2023-05-15
    Communication number: 15599-565047 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2023-04-25
    Posted date: 2023-05-15
    Communication number: 15599-565044 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2023-04-24
    Posted date: 2023-05-15
    Communication number: 15599-565036 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2023-04-05
    Posted date: 2023-05-15
    Communication number: 15599-561247 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Pierre-Yves Bourque, Director of Operations | Ministers Office | Innovation, Science and Economic Development Canada (ISED)
    • Jaxson Khan, Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Bianca Hossain, Policy advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2023-03-10
    Posted date: 2023-04-15
    Communication number: 15599-561244 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Chris Zou, Policy Advisor | Office of Minister International Trade | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Science and Technology
    Communication date: 2023-01-10
    Posted date: 2023-02-15
    Communication number: 15599-553546 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2023-01-04
    Posted date: 2023-02-15
    Communication number: 15599-553544 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Boulé, Director Regional Affairs | Minister's Office | Canadian Heritage (PCH)
    • Ashley Wright, Chief of Staff to the Minister | Minister's Office | Pacific Economic Development Canada (PacifiCan)
    • Jessie Pierre, Director of Policy | Ministers office | Federal Economic Development Agency for Southern Ontario (FedDev)
    • Zachary Nixon, Chief of Staff to the Minister | Minister's Office International Trade | Global Affairs Canada (GAC)
    • Chris Zou, Policy Advisor | Office of the Minister of International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Camille Benoit-Blouin, Special Assistant, Policy | Minister's Office International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2022-11-23
    Posted date: 2022-12-15
    Communication number: 15599-548550 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2022-09-29
    Posted date: 2022-10-15
    Communication number: 15599-542675 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Seamus O'Regan, Minister of Labour | Employment and Social Development Canada (ESDC)

    Subject Matter of the communication: Health, Industry
    Communication date: 2022-07-21
    Posted date: 2022-08-15
    Communication number: 15599-539071 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2022-06-28
    Posted date: 2022-07-04
    Communication number: 15599-536618 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Stephen Lucas, Sous-ministre | Health Products and food branch | Health Canada (HC)
    • Nancy Hamzawi, Assistant Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2022-06-17
    Posted date: 2022-07-04
    Communication number: 15599-536615 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Boulerice, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533291 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Richard Lehoux, Member of Parliament | House of Commons
    • Luc Berthold, Député | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Jacques Gourde, Member of Parliament | House of Commons
    • Bernard Genereux, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533290 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533289 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533288 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy | Minister's Office | Health Canada (HC)
    • Jamie Kippen, Chief of Staff | Minister's Office | Health Canada (HC)
    • Karl Sasseville, Deputy Chief of Staff | Minister's Office | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor | Minister's Office | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-05-31
    Posted date: 2022-06-05
    Communication number: 15599-533287 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Eric Costen, Senior Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2022-05-30
    Posted date: 2022-06-08
    Communication number: 15599-533578 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sandenga Yeba, Conseiller principal, Politiques - bureau de Quebec | Cabinet du ministre | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-03-25
    Posted date: 2022-03-25
    Communication number: 15599-527074 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2022-03-03
    Posted date: 2022-04-16
    Communication number: 15599-524431 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Sébastien Bock, Directeur des politiques | Santé Canada | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2022-02-14
    Posted date: 2022-02-14
    Communication number: 15599-522420 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Berthold, Député | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2022-01-27
    Posted date: 2022-02-14
    Communication number: 15599-522416 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Yves Duclos, Ministre de la santé | Cabinet du ministre | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2021-12-09
    Posted date: 2021-12-16
    Communication number: 15599-518449 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Berthold, Député | House of Commons

    Subject Matter of the communication: Health
    Communication date: 2021-12-06
    Posted date: 2021-12-16
    Communication number: 15599-518450 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean-Sebastien Bock, Director of Policy | Health Canada (HC)
    • Miro Froehlich, Policy Advisor | Health Canada (HC)

    Subject Matter of the communication: Health
    Communication date: 2021-12-01
    Posted date: 2021-12-03
    Communication number: 15599-516527 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Marc Miller, Minister of Indigenous Services | Indigenous Services Canada (ISC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2021-11-22
    Posted date: 2021-12-15
    Communication number: 15599-516636 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister of Innovation Science and Industry | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2021-11-09
    Posted date: 2021-12-15
    Communication number: 15599-516635 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Member of Parliament, Official Leader of the Opposition | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-07-07
    Posted date: 2021-08-16
    Communication number: 15599-511882 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Erin O'Toole, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Pierre Paul-Hus, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-06-21
    Posted date: 2021-07-15
    Communication number: 15599-509772 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Luc Thériault, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2021-06-04
    Posted date: 2021-07-15
    Communication number: 15599-509771 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Holly Duggan, Stakeholder Relations Advisor | Office of the Leader of the Opposition | House of Commons
    • Jordan Matte, Policy Advisor | Office of the Leader of the Opposition | House of Commons
    • Alexander MacDonald, Policy Advisor | Office of the Leader of the Opposition | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2021-06-01
    Posted date: 2021-07-15
    Communication number: 15599-506648 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Kathryn Nowers, Senior Policy Advisor | Office of the Minister | Health Canada (HC)
    • Sabina Saini, Chief of Staff | Office of the Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2021-05-20
    Posted date: 2021-06-15
    Communication number: 15599-506656 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean Yip, Member of Parliament | House of Commons
    • Joey Wong, Special Assistant to Jean Yip, MP | House of Commons

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2021-05-19
    Posted date: 2021-06-15
    Communication number: 15599-506654 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mike Lake, Member of Parliament | House of Commons
    • Jaclyn Preece, Constituency Manager | House of Commons
    • Nina Childs, Constituency Manager | House of Commons

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2021-05-19
    Posted date: 2021-06-15
    Communication number: 15599-506651 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Jean Yip, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry
    Communication date: 2021-04-30
    Posted date: 2021-05-15
    Communication number: 15599-503463 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Alexandre Deslongchamps, Director of Operations | Minister's Office | Natural Resources Canada (NRCan)

    Subject Matter of the communication: Health, Industry
    Communication date: 2021-04-29
    Posted date: 2021-05-15
    Communication number: 15599-503462 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister of Innovation Science and Economic Development (ISED) | Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Amanda Woodley, Policy Advisor | Ministers Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade
    Communication date: 2021-04-29
    Posted date: 2021-05-15
    Communication number: 15599-503461 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Celine Caira, Senior Policy Advisor | Minister's Office | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-04-26
    Posted date: 2021-05-15
    Communication number: 15599-503195 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Andy Fillmore, Member of Parliament, Halifax | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-04-22
    Posted date: 2021-05-15
    Communication number: 15599-503196 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Sean Fraser, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-04-16
    Posted date: 2021-05-15
    Communication number: 15599-503197 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2021-02-01
    Posted date: 2021-03-15
    Communication number: 15599-494289 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2021-02-01
    Posted date: 2021-03-15
    Communication number: 15599-494288 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • François-Philippe Champagne, Ministre | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Industry
    Communication date: 2021-02-01
    Posted date: 2021-02-01
    Communication number: 15599-494283 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Mike Dossou, Legislative Assistant | Member of Parliament's staff Dorval Lachine Lasalle | House of Commons

    Subject Matter of the communication: Research and Development
    Communication date: 2021-01-26
    Posted date: 2021-02-15
    Communication number: 15599-494287 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Chris d"Entremont, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2020-11-19
    Posted date: 2020-12-15
    Communication number: 15599-488652 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Shauna Roddey, Special Assistant | Innovation, Science and Economic Development Canada (ISED)
    • Mollie Anderson, Special Assistant | Innovation, Science and Economic Development Canada (ISED)
    • Liana Iannantuono, Special Assistant | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2020-10-20
    Posted date: 2020-11-16
    Communication number: 15599-485652 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Adam Van Koeverden, Député | House of Commons

    Subject Matter of the communication: Justice and Law Enforcement
    Communication date: 2020-10-07
    Posted date: 2020-10-07
    Communication number: 15599-483485 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Bardish Chagger, Ministre | Diversité et Inclusion et de la jeunesse | Canadian Heritage (PCH)
    • Jamie Kippen, Chef de Cabinet | Diversité et Inclusion et de la jeunesse | Canadian Heritage (PCH)

    Subject Matter of the communication: Justice and Law Enforcement
    Communication date: 2020-09-02
    Posted date: 2020-09-14
    Communication number: 15599-481712 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Tom Kmiec, Member of Parliament, Calgary | House of Commons
    • Kelly McCauley, Member of Parliament, Edmonton | House of Commons

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2020-07-13
    Posted date: 2020-08-15
    Communication number: 15599-477280 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Pierre Sabourin, Assistant Deputy Minister | Health Products and Food Branch | Health Canada (HC)

    Subject Matter of the communication: Health, Research and Development
    Communication date: 2020-04-09
    Posted date: 2020-05-15
    Communication number: 15599-471460 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament | House of Commons

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2020-02-11
    Posted date: 2020-03-16
    Communication number: 15599-464775 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Justin Trudeau, Prime Minister | Prime Minister's Office (PMO)

    Subject Matter of the communication: Health, Science and Technology, Research and Development
    Communication date: 2019-12-11
    Posted date: 2020-01-15
    Communication number: 15599-462333 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • William Monreau, Minister | Finance Canada (FIN)
    • Ben Chin, Chief of Staff | Finance Canada (FIN)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology, Research and Development
    Communication date: 2019-01-25
    Posted date: 2019-02-15
    Communication number: 15599-445212 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • Abby Hoffman, Assistant Deputy Minister | Strategic Policy Branch | Health Canada (HC)
    • Kathyrn Nowers, Director of Policy | Office of the Minister | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Eric Dagenais, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Paul Halucha, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • David McFarlane, Director of Policy | Office of the Minister | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Intellectual Property, International Trade, Science and Technology
    Communication date: 2018-10-05
    Posted date: 2018-11-15
    Communication number: 15599-435115 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Minister of Health | Health Canada (HC)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2018-06-28
    Posted date: 2018-07-16
    Communication number: 15599-430658 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Scott Brison, President, Treasury Board of Canada | Treasury Board Of Canada Secretariat (TBS)
    • Farees Nathoo, Special Assistant, Communications | Treasury Board Of Canada Secretariat (TBS)
    • Pat Dorsey, VP ACOA, PEI | Atlantic Canada Opportunities Agency (ACOA)

    Subject Matter of the communication: Health, Industry, Science and Technology, Research and Development
    Communication date: 2018-06-05
    Posted date: 2018-07-16
    Communication number: 15599-427971 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Susan Bincoletto, Ambassador | Global Affairs Canada (GAC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology, Research and Development
    Communication date: 2018-05-22
    Posted date: 2018-06-11
    Communication number: 15599-427973 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament, Dorval-Lachine-LaSalle | House of Commons

    Subject Matter of the communication: Health, Industry, International Trade, Science and Technology, Research and Development
    Communication date: 2018-05-08
    Posted date: 2018-06-15
    Communication number: 15599-425668 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ginette Petitpas Taylor, Health Minister | Health Canada (HC)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-05-05
    Posted date: 2018-06-15
    Communication number: 15599-426076 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Abby Hoffman, Assistant Deputy Minister | Strategic Policy | Health Canada (HC)
    • Eric Dagenais, Assistant Deputy Minister | Innovation Science and Economic Development | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Health Canada (HC)
    • John Knubley, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Gianluca Cairo, Chief of Staff | Innovation, Science and Economic Development Canada (ISED)
    • David MacFarlane, Director of Policy | Innovation, Science and Economic Development Canada (ISED)
    • Genevieve Hinse, Chief of Staff | Health Canada (HC)
    • Kathryn Nowers, Director of Policy | Health Canada (HC)
    • Hilary Travis, Special Assistant | Innovation, Science and Economic Development Canada (ISED)

    Subject Matter of the communication: Health, Industry, Science and Technology
    Communication date: 2018-04-03
    Posted date: 2018-04-12
    Communication number: 15599-423586 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Anju Dhillon, Member of Parliament - Dorval-Lachine-Lasalee | Patented Medicine Prices Review Board (PMPRB)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology, Research and Development
    Communication date: 2017-10-12
    Posted date: 2017-11-15
    Communication number: 15599-410410 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Ron Parker, Senior Assistant Deputy Minister | Industry Canada
    • Ron Parker, Senior Assistant Deputy Minister | Industry Canada | Industry Canada

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2010-06-01
    Posted date: 2010-07-28
    Communication number: 15599-152804 View monthly communication report
  • Novartis Pharmaceuticals Canada Inc.
    In-house Corporation
    Designated Public Office Holders who participated in the communication:
    • Louis Lévesque, Deputy Minister, International Trade | Foreign Affairs and International Trade Canada (DFAITC)

    Subject Matter of the communication: Health, Industry, Intellectual Property, Science and Technology
    Communication date: 2010-06-01
    Posted date: 2010-07-28
    Communication number: 15599-152803 View monthly communication report
Date Modified: